It began in 2018, at the Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. and the Centro Hospitalar de São João, E.P.E.
The research follows 566 patients who suffer from this disease, with the aim of studying the evolution of cognitive performance before and after the beginning of treatments. The aim is to verify whether hormone therapy, carried out in order to treat cancer, may potentiate cognitive decline in patients.
At recruitment, participants’ cognitive performance was assessed and information on their quality of life, sleep quality, levels of anxiety and depression, and level of health literacy was collected. Patients were reassessed 6 and 12 months after their date of entry to the study.
Cognitive performance and neuropsychological assessments are performed using the Brain on Track remote monitoring web tool and the Montreal Cognitive Assessment screening test.
The cohort aims to contribute to a more accurate characterisation of the overall burden of disease associated with prostate cancer treatment.
